FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069348084> ?p ?o ?g. }

• W2069348084 endingPage "395" @default.
• W2069348084 startingPage "388" @default.
• W2069348084 abstract "Abstract BACKGROUND. The current study was performed to compare the nonplatinum‐based combination of gemcitabine and vinorelbine (GV) with the combination of irinotecan and cisplatin (IP) as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer (NSCLC). METHODS. Patients were randomly assigned to received either irinotecan at a dose of 65 mg/m 2 plus cisplatin at a dose of 30 mg/m 2 (Arm A) or gemcitabine at a dose of 900 mg/m 2 plus vinorelbine at a dose of 25 mg/m 2 (Arm B), each of which was administered on Days 1 and 8 every 3 weeks as the first‐line therapy followed by crossover at the time of disease progression. RESULTS. A total of 146 patients were enrolled (75 patients in Arm A and 71 patients in Arm B); 138 patients were evaluable for tumor response and toxicity. During first‐line therapy, IP was found to result in more grade 2+ nausea and vomiting (toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]) (41% vs 12%; P = .0001) and alopecia (36% vs 10%; P = .0003). Pneumonitis was noted only with GV therapy (7% vs 0%; P = .058). During second‐line therapy, IP was found to result in more grade 3 diarrhea (17% vs 2%; P = .039) and GV featured more cases of grade 3+ neutropenia (78% vs 40%; P = .0003). IP tended to generate more tumor responses (38% vs 26% as first‐line therapy, and 30% vs 13% as second‐line therapy) compared with GV. IP also demonstrated a favorable trend in median progression‐free survival (4.6 months vs 3.8 months as first‐line therapy and 4.5 months vs 2.6 months as second‐line therapy) and overall survival (15.9 months vs 13.1 months; P = .3), but this difference was not statistically significant. The majority of patients who were refractory to IP also failed to respond to GV in the second‐line setting. CONCLUSIONS. The platinum‐based IP regimen appeared to be superior to the GV combination in terms of response rate. However, given the similar survival and better tolerability of the nonplatinum GV regimen, either treatment sequence would appear to be acceptable for the treatment of patients with advanced NSCLC. Cancer 2008. © 2008 American Cancer Society." @default.
• W2069348084 created "2016-06-24" @default.
• W2069348084 creator A5009145920 @default.
• W2069348084 creator A5011700088 @default.
• W2069348084 creator A5023055777 @default.
• W2069348084 creator A5055974749 @default.
• W2069348084 creator A5071037071 @default.
• W2069348084 creator A5073284312 @default.
• W2069348084 creator A5076575654 @default.
• W2069348084 date "2008-07-08" @default.
• W2069348084 modified "2023-10-17" @default.
• W2069348084 title "Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer" @default.
• W2069348084 cites W1585991298 @default.
• W2069348084 cites W1839238860 @default.
• W2069348084 cites W1977509822 @default.
• W2069348084 cites W2004718750 @default.
• W2069348084 cites W2005599761 @default.
• W2069348084 cites W2011406012 @default.
• W2069348084 cites W2018029718 @default.
• W2069348084 cites W2049601212 @default.
• W2069348084 cites W2051504572 @default.
• W2069348084 cites W2059308557 @default.
• W2069348084 cites W2079466869 @default.
• W2069348084 cites W2090927803 @default.
• W2069348084 cites W2096289704 @default.
• W2069348084 cites W2105202429 @default.
• W2069348084 cites W2105304787 @default.
• W2069348084 cites W2130652363 @default.
• W2069348084 cites W2133972163 @default.
• W2069348084 cites W2134667653 @default.
• W2069348084 cites W2145653040 @default.
• W2069348084 cites W2150358925 @default.
• W2069348084 cites W2154948351 @default.
• W2069348084 cites W2164529446 @default.
• W2069348084 cites W2254376071 @default.
• W2069348084 cites W4239714259 @default.
• W2069348084 doi "https://doi.org/10.1002/cncr.23582" @default.
• W2069348084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18484595" @default.
• W2069348084 hasPublicationYear "2008" @default.
• W2069348084 type Work @default.
• W2069348084 sameAs 2069348084 @default.
• W2069348084 citedByCount "22" @default.
• W2069348084 countsByYear W20693480842012 @default.
• W2069348084 countsByYear W20693480842013 @default.
• W2069348084 countsByYear W20693480842014 @default.
• W2069348084 countsByYear W20693480842015 @default.
• W2069348084 countsByYear W20693480842019 @default.
• W2069348084 countsByYear W20693480842021 @default.
• W2069348084 countsByYear W20693480842022 @default.
• W2069348084 crossrefType "journal-article" @default.
• W2069348084 hasAuthorship W2069348084A5009145920 @default.
• W2069348084 hasAuthorship W2069348084A5011700088 @default.
• W2069348084 hasAuthorship W2069348084A5023055777 @default.
• W2069348084 hasAuthorship W2069348084A5055974749 @default.
• W2069348084 hasAuthorship W2069348084A5071037071 @default.
• W2069348084 hasAuthorship W2069348084A5073284312 @default.
• W2069348084 hasAuthorship W2069348084A5076575654 @default.
• W2069348084 hasBestOaLocation W20693480841 @default.
• W2069348084 hasConcept C121608353 @default.
• W2069348084 hasConcept C126322002 @default.
• W2069348084 hasConcept C143998085 @default.
• W2069348084 hasConcept C2776256026 @default.
• W2069348084 hasConcept C2776694085 @default.
• W2069348084 hasConcept C2777063308 @default.
• W2069348084 hasConcept C2778239845 @default.
• W2069348084 hasConcept C2780258809 @default.
• W2069348084 hasConcept C2780259306 @default.
• W2069348084 hasConcept C2780350996 @default.
• W2069348084 hasConcept C29730261 @default.
• W2069348084 hasConcept C31760486 @default.
• W2069348084 hasConcept C526805850 @default.
• W2069348084 hasConcept C71924100 @default.
• W2069348084 hasConcept C90924648 @default.
• W2069348084 hasConceptScore W2069348084C121608353 @default.
• W2069348084 hasConceptScore W2069348084C126322002 @default.
• W2069348084 hasConceptScore W2069348084C143998085 @default.
• W2069348084 hasConceptScore W2069348084C2776256026 @default.
• W2069348084 hasConceptScore W2069348084C2776694085 @default.
• W2069348084 hasConceptScore W2069348084C2777063308 @default.
• W2069348084 hasConceptScore W2069348084C2778239845 @default.
• W2069348084 hasConceptScore W2069348084C2780258809 @default.
• W2069348084 hasConceptScore W2069348084C2780259306 @default.
• W2069348084 hasConceptScore W2069348084C2780350996 @default.
• W2069348084 hasConceptScore W2069348084C29730261 @default.
• W2069348084 hasConceptScore W2069348084C31760486 @default.
• W2069348084 hasConceptScore W2069348084C526805850 @default.
• W2069348084 hasConceptScore W2069348084C71924100 @default.
• W2069348084 hasConceptScore W2069348084C90924648 @default.
• W2069348084 hasIssue "2" @default.
• W2069348084 hasLocation W20693480841 @default.
• W2069348084 hasLocation W20693480842 @default.
• W2069348084 hasOpenAccess W2069348084 @default.
• W2069348084 hasPrimaryLocation W20693480841 @default.
• W2069348084 hasRelatedWork W1968731610 @default.
• W2069348084 hasRelatedWork W1972534072 @default.
• W2069348084 hasRelatedWork W1977727607 @default.
• W2069348084 hasRelatedWork W2135797559 @default.
• W2069348084 hasRelatedWork W2167571882 @default.

• next